Final Program International Conference on Myasthenia Gravis, Paris 2009 Organized by the EuroMyasthenia Network December 1, 2009 Etiological, genetic, and immunological aspects Chairs: A. Vincent and R. Mantegazza 9h00: Plenary Lecture: Aetiology of autoimmune diseases –JF. Bach 9h30: Is there a link between innate and autoimmunity in MG? – R. Mantegazza 9h50: Thymic changes in MG: Involvement of chemokines in thymic hyperplasia associated with an inflammatory environment – R. Le Panse 10h10: BAFF and autoimmune disease S. Ragheb
10h30-10h50: Coffee break
10h50: Immune regulation defect in MG – S. Berrih-Aknin 11h10: Genetic factors in autoimmune MG: present status and challenges – H. J. Garchon 11h30: Role of AIRE deficiency in thymoma-MG – A. Marx 11h50: Thymic changes in MG patients– I. Leite 12h10-12h25: Cytokine production of B-cell culture of MG patients – V. Yilmaz 12h30-14h00: Lunch break Muscle pathophysiology Chairs: B. Eymard and S. Fuchs 14h00: Plenary Lecture: Dok-7, Musk, and the development of the neuromuscular junction – Y. Yamanashi 14h30: The role of AChR associated proteins in autoimmune MG – P. Martinez 14h50: Pathogenic mechanisms underlying synaptic dysfunction in congenital myasthenic syndromes – D. Beeson 15h10: Identification of a mutation in agrin that causes congenital myasthenia and affects synapse function – D. Hantai 15h30: Anti-AChR antibodies increase IL-6 production by myoblasts and myotubes in vitro – S. Bougoin 15h45-16h00: Coffee break Experimental therapy Chairs: S. Tzartos and H. Kaminski 16h00: Plenary Lecture: Therapeutic approaches for MG studied in animal models – M. Souroujon 16h30: Complement-targeted therapy for MG – E. Tuzun 16h50: Mobilization of regulatory immune cells utilizing GM-CSF in EAMG – M. Meriggioli 17h10: Cholinergic anti-inflammatory signaling through α7 nicotinic acetylcholine receptor – T. Brenner 17h30: Development of safe and effective oral tolerogen for MG – S. H. Im 17h45-19h00: Poster session I December 2, 2009 Diagnosis issues and clinical therapy Chairs: M. De Baets and A. Melms 9h00: Plenary lecture: An update on diagnosis issues – A. Vincent 9h30: Recombinant antigenic domains for the study, diagnosis and treatment of MG – S. Tzartos 9h50: Status of the Trial for Thymectomy in nonthymomatous MG Patients Receiving Prednisone (MGTX) – H. Kaminski 10h10: Mycophenolate Mofetil (MMF) in AChR-antibody Positive MG: Outcomes in 102 patients – D. Sanders 10h30: Refractory MG and rituximab: long term follow-up of three patients and the “FORCE” trial – O. Benveniste 10h50: Classifying seronegative MG: a population based study – A. Carr 11h05-12h30: Poster session II with coffee break 12h30-14h00: Lunch break Public Health aspects Chairs: J. Verschuuren and A. Kostera –Pruszczyk 14h00: Plenary lecture: Myasthenia Gravis: from functioning and disability evaluation towards new healthcare approaches – A. Raggi 14h30: Long-term treatment in MG: A review – A. Evoli 14h50: MG in the elderly – J. Aarli 15h10: A questionnaire for assessing the impact of socio-economic factors in MG – A. Maniaol 15h30: The EuroMyasthenia project: What has it brought to the MG community? – N. Kerlero de Rosbo 15h50: Clinical and serological analysis of 175 patients with MG in Hungary Z. Illes 16h05-16h30: Coffee break 16h30-18h00: Session dedicated to interactions between clinicians, scientists and patients Medical panel: A. Evoli, A. Kostera-Pruszczyk, D. Sanders and C. Tallaksen
A medical panel will answer questions submitted by patients prior to the meeting through the conference website accessible via www.euromyasthenia.org
Directeur de la publication : Edwy Plenel«Après le Mediator, le scandale à venir est celui des traite-ments anti-Alzheimer !»Par Sylvain BourmeauArticle publié le mardi 04 janvier 2011Lacouverture de l’affaire du Mediator, ce médicament des labo-C’est un médecin qui écrit après le passage dans son cabinet d’unratoires Servier rendu responsable de la mort de 500 à 2.000 p